Cameron R. Wolfe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cameron R. Wolfe has a total of 314 co-authors. Here are the top co-authors by number of shared publications:
- Ricardo M. La Hoz
Division of Infectious Diseases and Geographic Medicine, University of Texas Southwestern Medical Center, Dallas, Texas
8 shared publications - Marian G. Michaels
UPMC Children's Hospital of Pittsburgh , Pittsburgh, Pennsylvania
6 shared publications - Julie M. Steinbrink
Department of Medicine, Division of Infectious Diseases, Duke University School of Medicine , Durham, North Carolina
5 shared publications - Lara Danziger-Isakov
Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio
5 shared publications - Emily M. Eichenberger
Division of Infectious Diseases Department of Medicine Emory University School of Medicine Atlanta Georgia USA
4 shared publications - Maricar Malinis
Division of Infectious Diseases Department of Medicine Vanderbilt University Medical Center Nashville Tennessee USA
4 shared publications
Latest Publications
- 25 August 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (12) , 2014-2015
Measles and varicella protection – surge in cases, but now a surge in hope!
- 25 August 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (12) , 2014-2015
Measles and varicella protection – surge in cases, but now a surge in hope!
- Open Access
- 12 May 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (4) , e70233
International Survey on Screening and Management of Strongyloidiasis in Solid Organ Transplant Patients
Background: Strongyloides stercoralis infection can be associated with high mortality in solid organ transplant (SOT) recipients, yet global practices regarding screening and management remain poorly characterized. We conducted an international survey to evaluate knowledge, screening, and management practices among healthcare workers (HCWs) involved in SOT care. Methods: We performed a cross‐sectional, web‐based survey of HCWs caring for SOT candidates and recipients. The survey assessed provider characteristics, knowledge of strongyloidiasis, as well as screening and management practices. Descriptive statistics were used to summarize responses. Results: A total of 101 HCWs responded, including 65 (64%) infectious diseases (ID) providers and 36 (36%) non‐ID providers. Knowledge gaps were identified regarding transmission and mortality, particularly among non‐ID providers. Overall, 85% of respondents reported screening SOT candidates for S. stercoralis ; among those who screen, serology is the most commonly used method. Screening strategies varied by geographic region, with universal screening more common in endemic areas and targeted screening in non‐endemic regions. Management practices, including approaches to indeterminate or negative test results, showed substantial heterogeneity. Conclusions: This international survey demonstrates considerable variability in knowledge, screening, and management of strongyloidiasis among HCWs involved in SOT care. These findings highlight opportunities for improved education, clearer guidance, and greater standardization of practices related to Strongyloides infection to avoid unnecessary morbidity. image
- 12 May 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (4) , e70233
Open AccessInternational Survey on Screening and Management of Strongyloidiasis in Solid Organ Transplant Patients
Background: Strongyloides stercoralis infection can be associated with high mortality in solid organ transplant (SOT) recipients, yet global practices regarding screening and management remain poorly characterized. We conducted an international survey to evaluate knowledge, screening, and management practices among healthcare workers (HCWs) involved in SOT care. Methods: We performed a cross‐sectional, web‐based survey of HCWs caring for SOT candidates and recipients. The survey assessed provider characteristics, knowledge of strongyloidiasis, as well as screening and management practices. Descriptive statistics were used to summarize responses. Results: A total of 101 HCWs responded, including 65 (64%) infectious diseases (ID) providers and 36 (36%) non‐ID providers. Knowledge gaps were identified regarding transmission and mortality, particularly among non‐ID providers. Overall, 85% of respondents reported screening SOT candidates for S. stercoralis ; among those who screen, serology is the most commonly used method. Screening strategies varied by geographic region, with universal screening more common in endemic areas and targeted screening in non‐endemic regions. Management practices, including approaches to indeterminate or negative test results, showed substantial heterogeneity. Conclusions: This international survey demonstrates considerable variability in knowledge, screening, and management of strongyloidiasis among HCWs involved in SOT care. These findings highlight opportunities for improved education, clearer guidance, and greater standardization of practices related to Strongyloides infection to avoid unnecessary morbidity. image
- 26 March 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (8) , 1991-2003
Organ-specific differences in the epidemiology of cytomegalovirus infections in high-risk (cytomegalovirus donor seropositive, recipient seronegative) solid organ transplant recipients with prolonged follow-up: A 10-year experience
- 26 March 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (8) , 1991-2003
Organ-specific differences in the epidemiology of cytomegalovirus infections in high-risk (cytomegalovirus donor seropositive, recipient seronegative) solid organ transplant recipients with prolonged follow-up: A 10-year experience
- Top Cited PapersOpen Access
- 18 February 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (5) , e1112-e1121
Respiratory Syncytial Virus Vaccination in Solid Organ Transplant Recipients: Interim Findings From a Phase 3 Trial of mRNA-1345
Background: Solid organ transplant (SOT) recipients are at increased risk for severe respiratory syncytial virus (RSV) disease due to chronic immunosuppression. Methods: In this ongoing, open-label, phase 3 trial, adults ≥18 years with a history of liver, kidney, or lung transplant received 2 doses of mRNA-1345 RSV vaccine (50 µg) 56 days apart. Primary endpoints were tolerability, safety, and RSV-A/RSV-B neutralizing antibody (nAb) responses on Day 85; secondary endpoints included immunogenicity on Days 29 and 181. Cell-mediated immunity was an exploratory endpoint assessed in a subset of participants. Results: 146/150 participants (median: age, 57 years; time since transplant, 4.7 years) received both doses. Reactogenicity was mild to moderate and transient. No vaccine-related discontinuations, deaths, adverse events of special interest (AESIs), or events of transplant rejection were reported within 28 days after any dose. One dose was immunogenic across all SOT types, with 4.9- and 3.4-fold increases in RSV-A/RSV-B nAb GMTs by Day 29, respectively. A second dose resulted in modest additional increases over baseline (RSV-A, 7.1-fold; RSV-B, 5.2-fold). Added benefit of the second dose was more apparent in participants with kidney and lung transplant, <2 years post-transplant, and on mycophenolate. Responses remained above baseline through Day 181. Polyfunctional CD4⁺ T-cell responses were robust and sustained; CD8⁺ responses were also observed. Conclusions: mRNA-1345 was well tolerated and immunogenic in SOT recipients. A single dose induced nAb responses across subgroups, with potential additional benefit from a second dose in specific groups. Durable antibody and cellular responses support mRNA-1345 as a preventive strategy for RSV in this vulnerable population. Clinical Trials Registration: NCT06067230.
- 18 February 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (5) , e1112-e1121
Top Cited PapersOpen AccessRespiratory Syncytial Virus Vaccination in Solid Organ Transplant Recipients: Interim Findings From a Phase 3 Trial of mRNA-1345
Background: Solid organ transplant (SOT) recipients are at increased risk for severe respiratory syncytial virus (RSV) disease due to chronic immunosuppression. Methods: In this ongoing, open-label, phase 3 trial, adults ≥18 years with a history of liver, kidney, or lung transplant received 2 doses of mRNA-1345 RSV vaccine (50 µg) 56 days apart. Primary endpoints were tolerability, safety, and RSV-A/RSV-B neutralizing antibody (nAb) responses on Day 85; secondary endpoints included immunogenicity on Days 29 and 181. Cell-mediated immunity was an exploratory endpoint assessed in a subset of participants. Results: 146/150 participants (median: age, 57 years; time since transplant, 4.7 years) received both doses. Reactogenicity was mild to moderate and transient. No vaccine-related discontinuations, deaths, adverse events of special interest (AESIs), or events of transplant rejection were reported within 28 days after any dose. One dose was immunogenic across all SOT types, with 4.9- and 3.4-fold increases in RSV-A/RSV-B nAb GMTs by Day 29, respectively. A second dose resulted in modest additional increases over baseline (RSV-A, 7.1-fold; RSV-B, 5.2-fold). Added benefit of the second dose was more apparent in participants with kidney and lung transplant, <2 years post-transplant, and on mycophenolate. Responses remained above baseline through Day 181. Polyfunctional CD4⁺ T-cell responses were robust and sustained; CD8⁺ responses were also observed. Conclusions: mRNA-1345 was well tolerated and immunogenic in SOT recipients. A single dose induced nAb responses across subgroups, with potential additional benefit from a second dose in specific groups. Durable antibody and cellular responses support mRNA-1345 as a preventive strategy for RSV in this vulnerable population. Clinical Trials Registration: NCT06067230.
- Open Access
- 23 July 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (7) , e70236
Hepatitis B Virus NAT Positive Donors in Non‐Hepatic Organ Transplant: Quantifying Viral Loads to Optimize Recipient Risk Stratification and Management in the Prevention of Donor‐Derived Infection
Transplantation is one of the few life‐saving therapies for patients with end‐stage organ disease, yet organ availability remains restrictive. Expanding donors to include those with hepatitis B virus (HBV) infection, incorporating HBV nucleic acid amplification testing (NAT) positive donors, could improve organ access. However, the risk of donor‐derived HBV transmission and recipient management of organs transplanted from HBV NAT‐positive donors, particularly in thoracic organ recipients, is limited. We conducted a single‐center retrospective study to assess the safety and outcomes in recipients of non‐hepatic organ transplants from HBV NAT‐positive donors. Over a 4.5‐year period, 25 transplant recipients, including 16 thoracic organ recipients, received organs from 22 unique, qualitative HBV NAT‐positive donors. All recipients were HBV surface antibody‐positive prior to transplant. Quantitative NAT was performed in 20/22 (91%) donors with values ranging from 0 to 1 280 000 IU/mL; 8/22 (36%) donors had HBV NAT values that were undetected or below the lower limit of quantification. All recipients were administered HBV immunoglobulin (HBIG) and received HBV active antiviral therapy post‐transplant. Recipients were followed post‐transplant for a median of 250 days (IQR: 169–467 days). No recipients developed de novo HBV infection characterized by HBV surface antigen (HBsAg) seroconversion, quantifiable HBV NAT detection, or sustained HBV core antibody (HbcAb) seroconversion post‐transplant. Similarly, no recipient developed liver dysfunction or died due to HBV infection. Quantifying HBV from NAT‐positive donors may better inform the risk of donor‐derived infection in recipients, and the use of these organs incorporating a multimodal prevention strategy could safely increase the donor pool.
- 23 July 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (7) , e70236
Open AccessHepatitis B Virus NAT Positive Donors in Non‐Hepatic Organ Transplant: Quantifying Viral Loads to Optimize Recipient Risk Stratification and Management in the Prevention of Donor‐Derived Infection
Transplantation is one of the few life‐saving therapies for patients with end‐stage organ disease, yet organ availability remains restrictive. Expanding donors to include those with hepatitis B virus (HBV) infection, incorporating HBV nucleic acid amplification testing (NAT) positive donors, could improve organ access. However, the risk of donor‐derived HBV transmission and recipient management of organs transplanted from HBV NAT‐positive donors, particularly in thoracic organ recipients, is limited. We conducted a single‐center retrospective study to assess the safety and outcomes in recipients of non‐hepatic organ transplants from HBV NAT‐positive donors. Over a 4.5‐year period, 25 transplant recipients, including 16 thoracic organ recipients, received organs from 22 unique, qualitative HBV NAT‐positive donors. All recipients were HBV surface antibody‐positive prior to transplant. Quantitative NAT was performed in 20/22 (91%) donors with values ranging from 0 to 1 280 000 IU/mL; 8/22 (36%) donors had HBV NAT values that were undetected or below the lower limit of quantification. All recipients were administered HBV immunoglobulin (HBIG) and received HBV active antiviral therapy post‐transplant. Recipients were followed post‐transplant for a median of 250 days (IQR: 169–467 days). No recipients developed de novo HBV infection characterized by HBV surface antigen (HBsAg) seroconversion, quantifiable HBV NAT detection, or sustained HBV core antibody (HbcAb) seroconversion post‐transplant. Similarly, no recipient developed liver dysfunction or died due to HBV infection. Quantifying HBV from NAT‐positive donors may better inform the risk of donor‐derived infection in recipients, and the use of these organs incorporating a multimodal prevention strategy could safely increase the donor pool.
- 1 July 2025
- Published by Wiley in Transplant Infectious Disease
- Vol. 27 (5) , e70066
Measles and Solid Organ Transplantation: Diagnosis, Treatment, and Prevention
The recent international resurgence of measles has led to significant public health concerns and poses significant risks to immunocompromised patients, including those who have undergone solid organ transplantation (SOT). SOT recipients may present atypically and are at an increased risk of severe complications of measles infection, underscoring the importance of preventative measures. This review summarizes contemporary data regarding measles transmission, the clinical presentation, diagnosis, and treatment of SOT recipients, as well as strategies for measles prevention, infection control considerations, postexposure prophylaxis, and opportunities for the mitigation of donor‐derived measles and measles vaccine viruses.
- 1 July 2025
- Published by Wiley in Transplant Infectious Disease
- Vol. 27 (5) , e70066
Measles and Solid Organ Transplantation: Diagnosis, Treatment, and Prevention
The recent international resurgence of measles has led to significant public health concerns and poses significant risks to immunocompromised patients, including those who have undergone solid organ transplantation (SOT). SOT recipients may present atypically and are at an increased risk of severe complications of measles infection, underscoring the importance of preventative measures. This review summarizes contemporary data regarding measles transmission, the clinical presentation, diagnosis, and treatment of SOT recipients, as well as strategies for measles prevention, infection control considerations, postexposure prophylaxis, and opportunities for the mitigation of donor‐derived measles and measles vaccine viruses.
- Open Access
- 24 May 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (3) , 439-450
Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY)
Background: We report an interim analysis of safety and efficacy of pemivibart in individuals with (cohort A) or without (cohort B) significant immunocompromise in the phase 3 CANOPY trial. Methods: Eligible participants (aged ≥18 years; negative for current severe acute respiratory syndrome coronavirus 2 infection) received 2 intravenous 4500-mg pemivibart infusions (cohort A) or were randomized 2:1 to receive blinded pemivibart or placebo infusions (cohort B) 90 days apart. Safety was a primary end point for both cohorts. The primary immunobridging end point for cohort A has been reported elsewhere. Composite incidence of reverse-transcription polymerase chain reaction–confirmed symptomatic coronavirus disease 2019 (COVID-19), COVID-19 hospitalization, and all-cause mortality was an exploratory end point. Results: In September–November 2023, 306 participants received pemivibart (cohort A), and 317 received pemivibart and 162 placebo (cohort B). The most common study drug–related adverse events were infusion-related reactions (cohort A: 11 of 306 [3.6%]; cohort B: 7 of 317 [2.2%] for pemivibart and 0 of 162 for placebo). Four of 623 participants (0.6%) who received pemivibart experienced anaphylactic reactions (serious in 2). In cohort A, the composite COVID-19 incidence through month 6 was 11 of 298 (3.7%; 2 deaths). In cohort B, 6 of 317 pemivibart (1.9%; no deaths) and 19 of 160 placebo (11.9%; no deaths) recipients met the end point through month 6 (84.1% standardized relative risk reduction [95% confidence interval, 60.9–93.5; nominal P < .001]), and 15 of 317 pemivibart (4.7%; 1 death) and 29 of 160 placebo (18.1%; no deaths) recipients met the end point through month 12 (73.9% standardized relative risk reduction [52.8–85.6; nominal P < .001]). Twelve-month protection was conferred with no additional dosing. Conclusions: Pemivibart provided prophylactic efficacy against COVID-19 and was well tolerated by most participants. Anaphylaxis was an important safety risk. Clinical Trials Registration: NCT06039449
- 24 May 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (3) , 439-450
Open AccessSafety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY)
Background: We report an interim analysis of safety and efficacy of pemivibart in individuals with (cohort A) or without (cohort B) significant immunocompromise in the phase 3 CANOPY trial. Methods: Eligible participants (aged ≥18 years; negative for current severe acute respiratory syndrome coronavirus 2 infection) received 2 intravenous 4500-mg pemivibart infusions (cohort A) or were randomized 2:1 to receive blinded pemivibart or placebo infusions (cohort B) 90 days apart. Safety was a primary end point for both cohorts. The primary immunobridging end point for cohort A has been reported elsewhere. Composite incidence of reverse-transcription polymerase chain reaction–confirmed symptomatic coronavirus disease 2019 (COVID-19), COVID-19 hospitalization, and all-cause mortality was an exploratory end point. Results: In September–November 2023, 306 participants received pemivibart (cohort A), and 317 received pemivibart and 162 placebo (cohort B). The most common study drug–related adverse events were infusion-related reactions (cohort A: 11 of 306 [3.6%]; cohort B: 7 of 317 [2.2%] for pemivibart and 0 of 162 for placebo). Four of 623 participants (0.6%) who received pemivibart experienced anaphylactic reactions (serious in 2). In cohort A, the composite COVID-19 incidence through month 6 was 11 of 298 (3.7%; 2 deaths). In cohort B, 6 of 317 pemivibart (1.9%; no deaths) and 19 of 160 placebo (11.9%; no deaths) recipients met the end point through month 6 (84.1% standardized relative risk reduction [95% confidence interval, 60.9–93.5; nominal P < .001]), and 15 of 317 pemivibart (4.7%; 1 death) and 29 of 160 placebo (18.1%; no deaths) recipients met the end point through month 12 (73.9% standardized relative risk reduction [52.8–85.6; nominal P < .001]). Twelve-month protection was conferred with no additional dosing. Conclusions: Pemivibart provided prophylactic efficacy against COVID-19 and was well tolerated by most participants. Anaphylaxis was an important safety risk. Clinical Trials Registration: NCT06039449
- Open Access
- 12 May 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (10) , 2057-2066
Beyond the HIV Organ Policy Equity Act: Roadmap to expanding kidney and liver transplants for people with human immunodeficiency virus utilizing grafts from donors with human immunodeficiency virus
- 12 May 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (10) , 2057-2066
Open AccessBeyond the HIV Organ Policy Equity Act: Roadmap to expanding kidney and liver transplants for people with human immunodeficiency virus utilizing grafts from donors with human immunodeficiency virus